

Heather G JÃ,rgensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9413840/publications.pdf>

Version: 2024-02-01

34
papers

2,327
citations

516215

16
h-index

476904

29
g-index

36
all docs

36
docs citations

36
times ranked

2633
citing authors

#	ARTICLE	IF	CITATIONS
1	Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. <i>Blood</i> , 2002, 99, 319-325.	0.6	1,107
2	Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. <i>Blood</i> , 2007, 109, 4016-4019.	0.6	283
3	JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. <i>Blood</i> , 2014, 124, 1492-1501.	0.6	134
4	Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. <i>Blood</i> , 2016, 128, 2671-2682.	0.6	89
5	Intermittent Exposure of Primitive Quiescent Chronic Myeloid Leukemia Cells to Granulocyte-Colony Stimulating Factor In vitro Promotes their Elimination by Imatinib Mesylate. <i>Clinical Cancer Research</i> , 2006, 12, 626-633.	3.2	86
6	Î±1-Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. <i>Blood</i> , 2002, 99, 713-715.	0.6	79
7	Nano-curcumin safely prevents streptozotocin-induced inflammation and apoptosis in pancreatic beta cells for effective management of Type 1 diabetes mellitus. <i>British Journal of Pharmacology</i> , 2017, 174, 2074-2084.	2.7	77
8	CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. <i>Blood</i> , 2017, 129, 199-208.	0.6	58
9	Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. <i>Journal of Clinical Medicine</i> , 2020, 9, 2934.	1.0	57
10	The Emerging Role of H3K9me3 as a Potential Therapeutic Target in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 705.	1.3	53
11	Neutralisation of TGFÎ² or binding of VLA-4 to fibronectin prevents rat tendon adhesion following transection. <i>Cytokine</i> , 2005, 30, 195-202.	1.4	40
12	Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2289-2300.	3.2	38
13	Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. <i>Experimental Hematology</i> , 2009, 37, 692-700.	0.2	31
14	Modulation of sialyl Lewis X dependent binding to E-Selectin by glycoforms of alpha-1-acid glycoprotein expressed in rheumatoid arthritis. , 1998, 12, 343-349.		30
15	Uptake of synthetic Low Density Lipoprotein by leukemic stem cells â€” a potential stem cell targeted drug delivery strategy. <i>Journal of Controlled Release</i> , 2010, 148, 380-387.	4.8	30
16	A KDM4A-PAF1-mediated epigenomic network is essential for acute myeloid leukemia cell self-renewal and survival. <i>Cell Death and Disease</i> , 2021, 12, 573.	2.7	20
17	Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. <i>Experimental Hematology</i> , 2005, 33, 1140-1146.	0.2	18
18	A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia. <i>Hematological Oncology</i> , 2001, 19, 89-106.	0.8	16

#	ARTICLE	IF	CITATIONS
19	Granulocyte-colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. <i>Cancer</i> , 2005, 103, 210-210.	2.0	15
20	Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal. <i>Cell Death and Disease</i> , 2018, 9, 927.	2.7	12
21	Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 51651-51664.	0.8	12
22	<scp>BCR</scp>â€œ<scp>ABL</scp>1 tyrosine kinase sustained <scp><i>MECOM</i></scp> expression in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2012, 157, 446-456.	1.2	9
23	Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells. <i>Advances in Biological Regulation</i> , 2021, 82, 100830.	1.4	8
24	Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. <i>Blood Cells, Molecules, and Diseases</i> , 2012, 48, 199-201.	0.6	5
25	Investigation of a minor groove-binding polyamide targeted to E2F1 transcription factor in chronic myeloid leukaemia (CML) cells. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 69, 119-122.	0.6	5
26	An investigation of targeted inhibition of transcription factor activity with pyrrole imidazole polyamide (PA) in chronic myeloid leukemia (CML) blast crisis cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2622-2625.	1.0	5
27	Transcriptional Regulation by the NFAT Family in Acute Myeloid Leukaemia. <i>Hemato</i> , 2021, 2, 556-571.	0.2	4
28	Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. <i>Experimental Hematology</i> , 2009, 37, 206-214.	0.2	2
29	Investigation into omacetaxine solution stability for <i>in vitro</i> study. <i>Biomedical Chromatography</i> , 2012, 26, 545-547.	0.8	2
30	Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS. <i>Pakistan Journal of Pharmaceutical Sciences</i> , 2011, 24, 285-91.	0.2	2
31	BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1569-1569.	0.6	0
32	Efficient Elimination of Acute Myeloid Leukemia Cells through Inhibition of KDM4A in Combination with PARP Inhibition. <i>Blood</i> , 2019, 134, 3756-3756.	0.6	0
33	<i>NFATC2</i> regulates Targets of MYC Signaling in MLL-AF9 AML. <i>Blood</i> , 2021, 138, 3301-3301.	0.6	0
34	Uncoupling p53 from an Embryonic Regulome Exhausts Quiescent CML Stem Cells through Inhibition of a HIF1alpha Molecular Program. <i>Blood</i> , 2021, 138, 1541-1541.	0.6	0